Skip to main content

ENMD-2076 Tartrate (C09-1131-213)

Aladdin

Catalog No.
C09-1131-213
Manufacturer No.
E655717-1ml
Manufacturer Name
Aladdin Scientific
Quantity
1
Unit of Measure
EA
Price: $224.84
List Price: $249.82

ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC 50 s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A , Flt3 , KDR/VEGFR2 , Flt4/VEGFR3 , FGFR1 , FGFR2 , Src , PDGFRα , respectively.In VitroENMD-2076 is selective toward

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account.

Adding to cart… The item has been added
ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC 50 s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A , Flt3 , KDR/VEGFR2 , Flt4/VEGFR3 , FGFR1 , FGFR2 , Src , PDGFRα , respectively.In VitroENMD-2076 is selective toward Aurora A versus Aurora B (IC 50 =350 nM). ENMD-2076 inhibits HUVEC growth with an IC 50 value of 0.15 mM. Against 10 human leukemia cell lines, the IC 50 values range from 0.025 to 0.53 mM. Within this panel, MV4:11 cells are the most sensitive cells by a factor of greater than 4. The lymphoma-derived U937 cell line treated with ENMD-2076 shows that the ENMD-2076 induces a dose-dependent increase in G2-M-phase arrest as well as the induction of apoptosis. ENMD-2076 inhibits cellular Flt3 ligand (FL)-induced Flt3 autophosphorylation in THP-1 cells, which have been shown to express FL-responsive wild-type Flt- 3 (18) with an IC 50 value of 28 nM. ENMD-2076 inhibits stem cell factor (SCF)-induced Kit autophosphorylation in MO7e cells with an IC 50 value of 40 nM. ENMD-2076 inhibits VEGFR2/KDR autophosphorylation with an IC 50 value of 7 nM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoENMD-2076 treatment results in statistically significant, dose dependent inhibition of tumor growth or tumor regression. Moreover, there is no correlation between tumor growth rate and antitumor efficacy, which would conceivably be expected for a mitotic kinase inhibitor, as fast growing (e.g., A375 melanoma) and slow-growing (e.g., HT29 colon carcinoma) tumors are similarly inhibited by ENMD-2076. ENMD-2076 is well tolerated at daily doses up to 302 mg/kg (equivalent to 200 mg/kg of the free base), with no weight loss or signs of morbidity noted in any study at this dose with the exception of the A375 model . MCE has not independently confirmed the accuracy of these methods. They are for reference only.IC50& Target:Aurora A 1.86 nM (IC 50 ) KDR 58.2 nM (IC 50 ) Flt-4 15.9 nM (IC 50 ) FGFR1 92.7 nM (IC 50 ) FGFR2 70.8 nM (IC 50 ) PDGFRα 56.4 nM (IC 50 ) Flt3 14 nM (IC 50 ). Specifications and Purity: 10mM in DMSO. Molecular Formula: C25H31N7O6. Molecular Weight: 525.56.
UPC:
12352005
Condition:
New
Availability:
8-12 weeks
Weight:
1.06 Ounces
HazmatClass:
No
WeightUOM:
LB
MPN:
E655717-1ml
CAS:
1453868-32-0
Product Size:
1ml


Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.


"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."

LAB DIRECTOR


"We utilized Cenmed's capabilities for a variety of projects around the world. They are a valued partner and supplier."

PHARMACEUTICAL SUPPLY CHAIN LEADER


"The reps are very good at finding products for customers in this period of supply chain issues."

SCOTT BEHMAN


"Your customer service has been excellent and makes me excited about purchasing with Cenmed in the future!!"

PROCUREMENT + BILLING COORDINATOR AT PHARMA.